SEARCH

SEARCH BY CITATION

References

  • 1
    The National Institute of Neurological Disorders Stroke and rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. NEJM 1995; 333: 15817.
  • 2
    Kaste M. Every day is a world stroke day: act now, be a stroke champion and a torchbearer! Stroke 2010; 41: 244950.
  • 3
    Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004; 61: 106670.
  • 4
    Saver JL, Gornbein J, Grotta J, Liebeskind D, Lutsep H, Schwamm L, Scott P, Starkman S. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window: joint outcome table analysis of the ECASS 3 trial. Stroke 2009; 40: 24337.
  • 5
    Hachinski V, Donnan GA, Gorelick PB, Hacke W, Cramer SC, Kaste M, Fisher M, Brainin M, Buchan AM, Lo EH, Skolnick BE, Furie KL, Hankey GJ, Kivipelto M, Morris J, Rothwell PM, Sacco RL, Smith SC Jr, Wang Y, Bryer A, et al. Stroke: working toward a prioritized world agenda. Stroke 2010; 41: 108499.
  • 6
    Moynihan B, Davis D, Pereira A, Cloud G, Markus HS. Delivering regional thrombolysis via a hub-and-spoke model. J R Soc Med 2010; 103: 3639.
  • 7
    Gladstone DJ, Rodan LH, Sahlas DJ, Lee L, Murray BJ, Ween JE, Perry JR, Chenkin J, Morrison LJ, Beck S, Black SE. A citywide prehospital protocol increases access to stroke thrombolysis in Toronto. Stroke 2009; 40: 38414.
  • 8
    Song S, Saver J. Growth of regional stroke systems of care in the United States in the first decade of the 21st century. Stroke 2011; 42: e340.
  • 9
    Schwamm LH, Smith E, Saver JL, Reeves M, Messe S, Bhatt D, Grau-Sepulveda M, Olson DW, Peterson EGF. Temporal trends in the use of IV tPA among all ischemic stroke patients presenting to GWTG-stroke hospitals (abstract). Stroke 2011; 42: e104.
  • 10
    Addo J, Bhalla A, Crichton S, Rudd AG, McKevitt C, Wolfe CDA. Provision of acute stroke care and associated factors in a multiethnic population: prospective study with the South London Stroke Register. BMJ 2011; 24: d744, doi: 10.1136/bmj.d744.
  • 11
    Grau AJ, Eicke M, Biegler MK, Faldum A, Bamberg C, Haass A, Hardt R, Hufschmidt A, Lowitzsch K, Marx J, Schmitt E, Schoenemann H, von Arnim W, Weiss H, Dienlin S. Quality monitoring of acute stroke care in Rhineland-Palatinate, Germany, 2001–2006. Stroke 2010; 41: 1495500.
  • 12
    del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O, Greenlee R, Brass L, Mohr JP, Feldmann E, Hacke W, Kase CS, Biller J, Gress D, Otis SM. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32: 7886.
  • 13
    Alexandrov AV, Demchuk AM, Burgin WS, Robinson DJ, Grotta JC. Ultrasound-enhanced thrombolysis for acute ischemic stroke: phase I. Findings of the CLOTBUST trial. J Neuroimaging 2004; 14: 1137.
  • 14
    Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, D. C.: National Academies Press, 2001.
  • 15
    Horowitz SH. Thrombolytic therapy in acute stroke: neurologists, get off your hands! Arch Neurol 1998; 55: 1557.
  • 16
    Burton T. Doctors push for more scans in stroke cases. Wall St J 2009; 21: Sect. D1.
  • 17
    American College of Emergency Physicians. Use of intravenous tPA for the management of acute stroke in the Emergency Department. http://www.acep.org/content.aspx?id=29834 2002. Accessed 8 June 2011.
  • 18
    Adams HP Jr, Kenton EJ III, Scheiber SC, Juul D. Vascular neurology: a new neurologic subspecialty. Neurology 2004; 63: 7746.
  • 19
    Josephson SA, Engstrom JW, Wachter RM. Neurohospitalists: an emerging model for inpatient neurological care. Ann Neurol 2008; 63: 13540.
  • 20
    Scott PA, Xu Z, Meurer WJ, Frederiksen SM, Haan MN, Westfall MW, Kothari SU, Morgenstern LB, Kalbfleisch JD. Attitudes and beliefs of Michigan emergency physicians toward tissue plasminogen activator use in stroke: baseline survey results from the INcreasing Stroke Treatment through INteractive behavioral Change Tactic (INSTINCT) Trial Hospitals. Stroke 2010; 41: 202632.
  • 21
    Alberts MJ, Hademenos G, Latchaw RE, Jagoda A, Marler JR, Mayberg MR, Starke RD, Todd HW, Viste KM, Girgus M, Shephard T, Emr M, Shwayder P, Walker MD. Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. JAMA 2000; 283: 31029.
  • 22
    Schwamm LH, Pancioli A, Acker JE III, Goldstein LB, Zorowitz RD, Shephard TJ, Moyer P, Gorman M, Johnston SC, Duncan PW, Gorelick P, Frank J, Stranne SK, Smith R, Federspiel W, Horton KB, Magnis E, Adams RJ. Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association’s Task Force on the Development of Stroke Systems. Stroke 2005; 36: 690703.
  • 23
    Demaerschalk BM, Durocher DL. How diagnosis-related group 559 will change the US medicare cost reimbursement ratio for stroke centers. Stroke 2007; 38: 130912.
  • 24
    Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W, Allen K, Mau J, Meier D, del Zoppo G, De Silva DA, Butcher KS, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695703.
  • 25
    Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009; CD000213.
  • 26
    Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 27582.
  • 27
    Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, Olson DM, Hernandez AF, Peterson ED, Schwamm LH. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation 2011; 123: 7508.
  • 28
    Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, Shinohara Y, Yamaguchi T. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010; 41: 19849.
  • 29
    Chao AC, Hsu HY, Chung CP, Liu CH, Chen CH, Teng MM, Peng GS, Sheng WY, Hu HH. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study. Stroke 2010; 41: 88590.
  • 30
    Schwamm LH, Reeves MJ, Pan W, Smith EE, Frankel MR, Olson D, Zhao X, Peterson E, Fonarow GC. Race/ethnicity, quality of care, and outcomes in ischemic stroke. Circulation 2010; 121: 1492501.
  • 31
    Acker JE III, Pancioli AM, Crocco TJ, Eckstein MK, Jauch EC, Larrabee H, Meltzer NM, Mergendahl WC, Munn JW, Prentiss SM, Sand C, Saver JL, Eigel B, Gilpin BR, Schoeberl M, Solis P, Bailey JR, Horton KB, Stranne SK. Implementation strategies for emergency medical services within stroke systems of care: a policy statement from the American Heart Association/American Stroke Association Expert Panel on Emergency Medical Services Systems and the Stroke Council. Stroke 2007; 38: 3097115.
  • 32
    Switzer JA, Hall C, Gross H, Waller J, Nichols FT, Wang S, Adams RJ, Hess DC. A web-based telestroke system facilitates rapid treatment of acute ischemic stroke patients in rural emergency departments. J Emerg Med 2009; 36: 128.
  • 33
    Saver JL. Time is brain – quantified. Stroke 2006; 37: 2636.
  • 34
    Lansberg M, Bluhmki E, Saver J. Number needed to treat estimates for tPA per 90-minute time interval. Stroke 2008; 39: 560.
  • 35
    Marler JR, Winters Jones P, Emr M. The National Institute of Neurological Disorders and Stroke: Proceedings of National Symposium on Rapid Identification and Treatment of Acute Stroke. Bethesda, MD: National Institute of Neurological Disorders and Stroke, 1997.
  • 36
    Summers D, Leonard A, Wentworth D, Saver JL, Simpson J, Spilker JA, Hock N, Miller E, Mitchell PH. Comprehensive overview of nursing and interdisciplinary care of the acute ischemic stroke patient: a scientific statement from the American Heart Association. Stroke 2009; 40: 291144.
  • 37
    Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, Parsons M, Roine RO, Toni D, Ringleb P. Implementation and outcome of thrombolysis with alteplase 3–4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010; 9: 86674.
  • 38
    Majersik JJ, Smith MA, Zahuranec DB, Sanchez BN, Morgenstern LB. Population-based analysis of the impact of expanding the time window for acute stroke treatment. Stroke 2007; 38: 32137.
  • 39
    Khatri P, Khoury JC, Alwell K, Moomaw JC, Kissela BM, Woo D, Flaherty ML, Adeoye O, Ferioli S, Kleindorfer DO. The public health impact of an effective acute treatment for mild ischemic strokes (abstract). Stroke 2011; 42: e66.
  • 40
    Weimar C, Mieck T, Buchthal J, Ehrenfeld CE, Schmid E, Diener HC. Neurologic worsening during the acute phase of ischemic stroke. Arch Neurol 2005; 62: 3937.
  • 41
    Sato S, Toyoda K, Uehara T, Toratani N, Yokota C, Moriwaki H, Naritomi H, Minematsu K. Baseline NIH Stroke Scale Score predicting outcome in anterior and posterior circulation strokes. Neurology 2008; 70: 23717.
  • 42
    Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001; 56: 101520.
  • 43
    Fischer U, Baumgartner A, Arnold M, Nedeltchev K, Gralla J, Marco De Marchis G, Kappeler L, Mono M-L, Brekenfeld C, Schroth G, Mattle HP. What is a minor stroke? Stroke 2010; 41: 6616.
  • 44
    Rajajee V, Kidwell C, Starkman S, Ovbiagele B, Alger JR, Villablanca P, Vinuela F, Duckwiler G, Jahan R, Fredieu A, Suzuki S, Saver JL. Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology 2006; 67: 9804.
  • 45
    Singer OC, Humpich MC, Fiehler J, Albers GW, Lansberg MG, Kastrup A, Rovira A, Liebeskind DS, Gass A, Rosso C, Derex L, Kim JS, Neumann-Haefelin T. Risk for symptomatic intracerebral hemorrhage after thrombolysis assessed by diffusion-weighted magnetic resonance imaging. Ann Neurol 2008; 63: 5260.
  • 46
    Lee SJ, Saver JL, Liebeskind DS, Ali L, Ovbiagele B, Kim D, Vespa P, Froehler M, Tenser M, Gadhia J, Starkman S. Safety of intravenous fibrinolysis in imaging-confirmed single penetrator artery infarcts. Stroke 2010; 41: 258791.
  • 47
    Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R, Alwell K, Gebel J, Szaflarski J, Pancioli A, Jauch E, Moomaw C, Shukla R, Broderick JP. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke 2004; 35: e279.
  • 48
    Huang P, Khor G-T, Chen C-H, Lin R-T, Liu C-K. Eligibility and rate of treatment for recombinant tissue plasminogen activator in acute ischemic stroke using different criteria. Acad Emerg Med 2011; 18: 2738.
  • 49
    Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002; 59: 8627.
  • 50
    Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke 2007; 38: 227983.
  • 51
    Abu Fanne R, Nassar T, Yarovoi S, Rayan A, Lamensdorf I, Karakoveski M, Vadim P, Jammal M, Cines DB, Higazi AA. Blood–brain barrier permeability and tPA-mediated neurotoxicity. Neuropharmacology 2010; 58: 97280.
  • 52
    Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282: 200311.
  • 53
    Davydov L, Cheng JW. Tenecteplase: a review. Clin Ther 2001; 23: 98297.
  • 54
    Lyden P, TNK for Stroke Investigators. Pilot study of tenecteplase (TNK) in acute ischemic stroke: preliminary report. Stroke 2003; 34: 246A.
  • 55
    Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, Fanale C, Libman R, Kwiatkowski TG, Llinas RH, Levine SR, Johnston KC, Buchsbaum R, Levy G, Levin B. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010; 41: 70711.
  • 56
    Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003; 34: 53743.
  • 57
    Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, Kaste M, Lipka LJ, Pedraza S, Ringleb PA, Rowley HA, Schneider D, Schwamm LH, Leal JS, Sohngen M, Teal PA, Wilhelm-Ogunbiyi K, Wintermark M, Warach S. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009; 8: 14150.
  • 58
    Weinheimer CJ, James HL, Kalyan NK, Wilhelm J, Lee SG, Hung PP, Sobel BE, Bergmann SR. Induction of sustained patency after clot-selective coronary thrombolysis with Hybrid-B, a genetically engineered plasminogen activator with a prolonged biological half-life. Circulation 1991; 83: 142936.
  • 59
    Hu HH, Teng MM, Hsu LC, Wong WJ, Wang LM, Luk YO, Chern CM, Soong BW, Sheng WY. A pilot study of a new thrombolytic agent for acute ischemic stroke in Taiwan within a five-hour window. Stroke 2006; 37: 9189.
  • 60
    Marder VJ, Stewart D. Towards safer thrombolytic therapy. Semin Hematol 2002; 39: 20616.
  • 61
    Marder VJ, Jahan R, Gruber T, Goyal A, Arora V. Thrombolysis with plasmin: implications for stroke treatment. Stroke 2010; 41: S459.
  • 62
    Tsivgoulis G, Eggers J, Ribo M, Perren F, Saqqur M, Rubiera M, Sergentanis TN, Vadikolias K, Larrue V, Molina CA, Alexandrov AV. Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies. Stroke 2010; 41: 2807.
  • 63
    Daffertshofer M, Gass A, Ringleb P, Sitzer M, Sliwka U, Els T, Sedlaczek O, Koroshetz WJ, Hennerici MG. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke 2005; 36: 14416.
  • 64
    Alexandrov AV. Ultrasound identification and lysis of clots. Stroke 2004; 35(11 Suppl 1): 27225.
  • 65
    Molina CA, Barreto AD, Tsivgoulis G, Sierzenski P, Malkoff MD, Rubiera M, Gonzales N, Mikulik R, Pate G, Ostrem J, Singleton W, Manvelian G, Unger EC, Grotta JC, Schellinger PD, Alexandrov AV. Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial. Ann Neurol 2009; 66: 2838.
  • 66
    Straub S, Junghans U, Jovanovic V, Wittsack HJ, Seitz RJ, Siebler M. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion. Stroke 2004; 35: 7059.
  • 67
    Seitz RJ, Meisel S, Moll M, Wittsack H-J, Junghans U, Siebler M. The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions. Neurology 2004; 62: 21102.
  • 68
    Gahn G, Kunz A, Putz V, Becker U, Goldhagen T, Hahn G, Dzialowski I, Disque C, von Kummer R. Recanalization of middle cerebral artery occlusion after either t-PA or t-PA combined with abciximab. Stroke 2004; 35: 287 (abstract).
  • 69
    Warach S. ReoPro Retavase Reperfusion of Stroke Safety Study – Imaging Evaluation [online]. Available at: http://www.strokecenter.org/trials/trialDetail.aspx?tid=462&search_string=rosie. Accessed 22 March.
  • 70
    Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, del Zoppo G, Kleindorfer D, Woo D, Khatri P, Castaldo J, Frey J, Gebel J Jr, Kasner S, Kidwell C, Kwiatkowski T, Libman R, Mackenzie R, Scott P, Starkman S, et al. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke 2008; 39: 326876.
  • 71
    Barreto A, Grotta JC. The argatroban and tPA stroke study. Prog Neurother Neuropsychopharmacol, 2008; 3: 3547.
  • 72
    Saver JL. Target brain: neuroprotection and neurorestoration in ischemic stroke. Rev Neurol Dis 2010; 7(Suppl 1): S1421.
  • 73
    Stewart D, Marder VJ, Starkman S, Saver JL. Magnesium sulfate neither potentiates nor inhibits tissue plasminogen activator-induced thrombolysis. J Thromb Haemost 2006; 4: 15759.
  • 74
    Saver JL, Kidwell C, Eckstein M, Starkman S. Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial. Stroke 2004; 35: e1068.
  • 75
    Dong X, Song YN, Liu WG, Guo XL. Mmp-9, a potential target for cerebral ischemic treatment. Curr Neuropharmacol 2009; 7: 26975.
  • 76
    Liu W, Hendren J, Qin X-J, Liu KJ. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia. Stroke 2009; 40: 252631.
  • 77
    Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemoto S, Miyamoto S, Sasaki M, Inoue T. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 2007; 38: 26339.
  • 78
    Lee M, Hong KS, Saver JL. Efficacy of intra-arterial fibrinolysis for acute ischemic stroke: meta-analysis of randomized controlled trials. Stroke 2010; 41: 9327.
  • 79
    Leary MC, Saver JL, Gobin YP, Jahan R, Duckwiler GR, Vinuela F, Kidwell CS, Frazee J, Starkman S. Beyond tissue plasminogen activator: mechanical intervention in acute stroke. Ann Emerg Med 2003; 41: 83846.
  • 80
    Caplan L, Gorelick P, Hier D. Race, sex and occlusive cerebrovascular disease: a review. Stroke 1986; 17: 64855.
  • 81
    Qureshi AI, Siddiqui AM, Suri MF, Kim SH, Ali Z, Yahia AM, Lopes DK, Boulos AS, Ringer AJ, Saad M, Guterman LR, Hopkins LN. Aggressive mechanical clot disruption and low-dose intra-arterial third-generation thrombolytic agent for ischemic stroke: a prospective study. Neurosurgery 2002; 51: 131927.
  • 82
    Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007; 38: 96773.
  • 83
    Velat GJ, Hoh BL, Levy EI, Mocco J. Primary intracranial stenting in acute ischemic stroke. Curr Cardiol Rep 2010; 12: 149.
  • 84
    Levy EI, Siddiqui AH, Crumlish A, Snyder KV, Hauck EF, Fiorella DJ, Hopkins LN, Mocco J. First Food and Drug Administration-approved prospective trial of primary intracranial stenting for acute stroke: SARIS (stent-assisted recanalization in acute ischemic stroke). Stroke 2009; 40: 35526.
  • 85
    Penumbra Pivotal Stroke Trial Investigators. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke 2009; 40: 27618.
  • 86
    Saver JL, Liebeskind DS, Nogueira RG, Jahan R. Need to clarify thrombolysis in myocardial ischemia (TIMI) scale scoring method in the Penumbra Pivotal Stroke Trial. Stroke 2010; 41: e1156.
  • 87
    Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, Lutsep HL, Nesbit GM, Grobelny T, Rymer MM, Silverman IE, Higashida RT, Budzik RF, Marks MP. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005; 36: 14328.
  • 88
    Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, Lutsep HL, Rymer MM, Higashida RT, Starkman S, Gobin YP, for the Multi MI. Mechanical thrombectomy for acute ischemic stroke: final results of the multi MERCI trial. Stroke 2008; 39: 120512.
  • 89
    Mpotsaris A, Bussmeyer M, Loehr C, Oelerich M, Buchner H, Weber W. Mechanical thrombectomy in severe acute stroke: preliminary results of the Solitaire stent. J Neurol Neurosurg Psychiatry 2011. [Epub ahead of print].
  • 90
    Castano C, Dorado L, Guerrero C, Millan M, Gomis M, Perez de la Ossa N, Castellanos M, Garcia MR, Domenech S, Davalos A. Mechanical thrombectomy with the Solitaire AB device in large artery occlusions of the anterior circulation: a pilot study. Stroke 2010; 41: 183640.
  • 91
    Marder VJ, Chute DJ, Starkman S, Abolian AM, Kidwell C, Liebeskind D, Ovbiagele B, Vinuela F, Duckwiler G, Jahan R, Vespa PM, Selco S, Rajajee V, Kim D, Sanossian N, Saver JL. Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke. Stroke 2006; 37: 208693.
  • 92
    Liebeskind DS, Sanossian N, Yong WH, Starkman S, Tsang MP, Moya AL, Zheng DD, Abolian AM, Kim D, Ali LK, Shah SH, Towfighi A, Ovbiagele B, Kidwell CS, Tateshima S, Jahan R, Duckwiler GR, Vinuela F, Salamon N, Villablanca JP, et al. CT and MRI early vessel signs reflect clot composition in acute stroke. Stroke 2011; 42: 12374.
  • 93
    Molina CA, Saver JL. Extending reperfusion therapy for acute ischemic stroke: emerging pharmacological, mechanical, and imaging strategies. Stroke 2005; 36: 231120.
  • 94
    Khatri P, Hill MD, Palesch YY, Spilker J, Jauch EC, Carrozzella JA, Demchuk AM, Martin R, Mauldin P, Dillon C, Ryckborst KJ, Janis S, Tomsick TA, Broderick JP. Methodology of the interventional management of stroke III trial. Int J Stroke 2008; 3: 1307.
  • 95
    Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004; 35: 90411.
  • 96
    Mazighi M, Serfaty JM, Labreuche J, Laissy JP, Meseguer E, Lavallee PC, Cabrejo L, Slaoui T, Guidoux C, Lapergue B, Klein IF, Olivot JM, Abboud H, Simon O, Niclot P, Nifle C, Touboul PJ, Raphaeli G, Gohin C, Claeys ES, et al. Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet Neurol 2009; 8: 8029.